HRP20100678T1 - Derivati heteroariluree korisni kao inhibitori chk1 - Google Patents
Derivati heteroariluree korisni kao inhibitori chk1 Download PDFInfo
- Publication number
- HRP20100678T1 HRP20100678T1 HR20100678T HRP20100678T HRP20100678T1 HR P20100678 T1 HRP20100678 T1 HR P20100678T1 HR 20100678 T HR20100678 T HR 20100678T HR P20100678 T HRP20100678 T HR P20100678T HR P20100678 T1 HRP20100678 T1 HR P20100678T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- Prior art date
Links
- -1 Heteroaryl urea derivatives Chemical class 0.000 title abstract 2
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Spoj, naznačen time što je 1-[5-brom-4-metil-2-S-(morfolin-2-ilmetoksi)fenil]-3-(5-metilpirazin-2-il)urea ili njezina farmaceutski prihvatljiva sol. Patent sadrži još 4 patentna zahtjeva.
Claims (5)
1. Spoj, naznačen time što je 1-[5-brom-4-metil-2-S-(morfolin-2-ilmetoksi)fenil]-3-(5-metilpirazin-2-il)urea ili njezina farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv razrjeđivač ili podlogu.
3. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća.
5. Upotreba spoja u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66602605P | 2005-03-29 | 2005-03-29 | |
PCT/US2006/011584 WO2006105262A1 (en) | 2005-03-29 | 2006-03-29 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100678T1 true HRP20100678T1 (hr) | 2011-02-28 |
Family
ID=36677174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100678T HRP20100678T1 (hr) | 2005-03-29 | 2010-12-07 | Derivati heteroariluree korisni kao inhibitori chk1 |
Country Status (32)
Country | Link |
---|---|
US (1) | US8093244B2 (hr) |
EP (2) | EP2330105A1 (hr) |
JP (2) | JP5117374B2 (hr) |
KR (2) | KR100912998B1 (hr) |
CN (2) | CN102219784A (hr) |
AR (1) | AR056645A1 (hr) |
AT (1) | ATE490248T1 (hr) |
AU (1) | AU2006230337B2 (hr) |
BR (1) | BRPI0609667A2 (hr) |
CA (1) | CA2602199C (hr) |
CR (1) | CR9395A (hr) |
CY (1) | CY1111240T1 (hr) |
DE (1) | DE602006018590D1 (hr) |
DK (1) | DK1869020T3 (hr) |
EA (1) | EA011287B1 (hr) |
ES (1) | ES2356068T3 (hr) |
HK (1) | HK1119670A1 (hr) |
HR (1) | HRP20100678T1 (hr) |
IL (1) | IL185481A0 (hr) |
MA (1) | MA29439B1 (hr) |
MX (1) | MX2007012116A (hr) |
NO (1) | NO20074944L (hr) |
NZ (1) | NZ561458A (hr) |
PL (1) | PL1869020T3 (hr) |
PT (1) | PT1869020E (hr) |
RS (1) | RS51616B (hr) |
SI (1) | SI1869020T1 (hr) |
TN (1) | TNSN07369A1 (hr) |
TW (1) | TWI375559B (hr) |
UA (1) | UA92164C2 (hr) |
WO (1) | WO2006105262A1 (hr) |
ZA (1) | ZA200707715B (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008067027A2 (en) | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
CN101200429B (zh) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法 |
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
EP3411036B1 (en) | 2016-02-04 | 2021-12-29 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
KR20230042756A (ko) | 2016-03-15 | 2023-03-29 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
MX2019011506A (es) * | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2021183973A1 (en) * | 2020-03-13 | 2021-09-16 | Research Development Foundation | Methods for diagnosing and treating cancers |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293552A (en) | 1978-02-27 | 1981-10-06 | Eli Lilly And Company | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas |
US6174993B1 (en) | 1997-05-21 | 2001-01-16 | The Children's Medical Center Corp. | Short peptides which selectively modulate the activity of serine/threonine kinases |
GB9718952D0 (en) | 1997-09-05 | 1997-11-12 | Medical Res Council | Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods |
US6218109B1 (en) | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
CN1278725A (zh) | 1997-10-06 | 2001-01-03 | 巴斯福股份公司 | 茚并[1,2-c]-、萘并[1,2-c]-和苯并[6,7]芳庚并[1,2-c]吡唑类衍生物 |
EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
AU3974001A (en) | 2000-02-03 | 2001-08-14 | Ali R. Fattaey | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
WO2001062900A1 (en) | 2000-02-25 | 2001-08-30 | The Regents Of The University Of California. | Scytonemin and methods of using thereof |
US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
US6534691B2 (en) | 2000-07-18 | 2003-03-18 | E. I. Du Pont De Nemours And Company | Manufacturing process for α-olefins |
ATE295354T1 (de) | 2000-08-18 | 2005-05-15 | Agouron Pharma | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen |
MXPA03006478A (es) | 2001-01-26 | 2003-09-22 | Pharmacia Italia Spa | Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales. |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
US7064215B2 (en) | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
US7166639B2 (en) | 2001-10-04 | 2007-01-23 | Smithkline Beecham Corporation | NF-κB inhibitors |
WO2003029241A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
WO2003028731A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003224341A1 (en) | 2002-04-26 | 2003-11-10 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
US7202244B2 (en) * | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
US20040034038A1 (en) | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
ATE404564T1 (de) | 2003-01-09 | 2008-08-15 | Pfizer | Diazepinoindolderivate als kinaseinhibitoren |
WO2006012308A1 (en) | 2004-06-25 | 2006-02-02 | Icos Corporation | Bisarylurea derivatives useful for inhibiting chk1 |
CA2679908A1 (en) | 2009-09-23 | 2011-03-23 | Shell Internationale Research Maatschappij B.V. | Closed loop solvent extraction process for oil sands |
CN104407475B (zh) | 2014-12-04 | 2017-04-05 | 厦门天马微电子有限公司 | 液晶显示面板 |
-
2006
- 2006-03-29 SI SI200630870T patent/SI1869020T1/sl unknown
- 2006-03-29 DE DE602006018590T patent/DE602006018590D1/de active Active
- 2006-03-29 DK DK06748900.5T patent/DK1869020T3/da active
- 2006-03-29 KR KR1020077022281A patent/KR100912998B1/ko not_active IP Right Cessation
- 2006-03-29 AU AU2006230337A patent/AU2006230337B2/en not_active Ceased
- 2006-03-29 JP JP2008504337A patent/JP5117374B2/ja not_active Expired - Fee Related
- 2006-03-29 MX MX2007012116A patent/MX2007012116A/es active IP Right Grant
- 2006-03-29 UA UAA200710711A patent/UA92164C2/ru unknown
- 2006-03-29 NZ NZ561458A patent/NZ561458A/en not_active IP Right Cessation
- 2006-03-29 RS RS20110053A patent/RS51616B/en unknown
- 2006-03-29 PT PT06748900T patent/PT1869020E/pt unknown
- 2006-03-29 US US11/908,416 patent/US8093244B2/en not_active Expired - Fee Related
- 2006-03-29 EP EP10189889A patent/EP2330105A1/en not_active Withdrawn
- 2006-03-29 KR KR1020097002925A patent/KR20090031459A/ko not_active Application Discontinuation
- 2006-03-29 TW TW095110859A patent/TWI375559B/zh not_active IP Right Cessation
- 2006-03-29 BR BRPI0609667-0A patent/BRPI0609667A2/pt not_active IP Right Cessation
- 2006-03-29 ES ES06748900T patent/ES2356068T3/es active Active
- 2006-03-29 PL PL06748900T patent/PL1869020T3/pl unknown
- 2006-03-29 CN CN2011101022112A patent/CN102219784A/zh active Pending
- 2006-03-29 CA CA2602199A patent/CA2602199C/en not_active Expired - Fee Related
- 2006-03-29 AT AT06748900T patent/ATE490248T1/de active
- 2006-03-29 EA EA200702094A patent/EA011287B1/ru not_active IP Right Cessation
- 2006-03-29 CN CN2006800101504A patent/CN101151259B/zh not_active Expired - Fee Related
- 2006-03-29 EP EP06748900A patent/EP1869020B1/en active Active
- 2006-03-29 WO PCT/US2006/011584 patent/WO2006105262A1/en active Application Filing
- 2006-03-29 AR ARP060101226A patent/AR056645A1/es unknown
-
2007
- 2007-08-23 IL IL185481A patent/IL185481A0/en unknown
- 2007-09-07 ZA ZA200707715A patent/ZA200707715B/xx unknown
- 2007-09-26 CR CR9395A patent/CR9395A/es unknown
- 2007-09-28 TN TNP2007000369A patent/TNSN07369A1/en unknown
- 2007-10-01 NO NO20074944A patent/NO20074944L/no not_active Application Discontinuation
- 2007-10-26 MA MA30325A patent/MA29439B1/fr unknown
-
2008
- 2008-06-25 HK HK08107066.6A patent/HK1119670A1/xx not_active IP Right Cessation
-
2009
- 2009-05-20 JP JP2009122107A patent/JP2009227682A/ja active Pending
-
2010
- 2010-12-07 HR HR20100678T patent/HRP20100678T1/hr unknown
-
2011
- 2011-02-03 CY CY20111100117T patent/CY1111240T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100678T1 (hr) | Derivati heteroariluree korisni kao inhibitori chk1 | |
PH12019500712A1 (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
TW200630347A (en) | Quinazoline derivatives | |
MX2009002010A (es) | Derivados de heteroarilo como inhibidores de la proteina cinasa. | |
GEP20105024B (en) | Fused heterocyclic compound | |
TW200628466A (en) | Quinazoline derivatives | |
WO2007048066A3 (en) | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators | |
MX2007007098A (es) | Derivados de pirrol que tienen actividad antagonista del receptor crth2. | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
TW200628452A (en) | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | |
TW200745040A (en) | Quinoline derivatives | |
CY1116885T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου | |
EA200800502A1 (ru) | Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения | |
PL1888514T3 (pl) | Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych | |
MY145647A (en) | (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states) | |
TW200639156A (en) | New compounds | |
WO2007065662A3 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
SE0303541D0 (sv) | New compounds | |
HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors | |
TW200719899A (en) | Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents | |
TW200745085A (en) | Quinoline derivatives | |
TW200510427A (en) | Novel fused heterocycles and uses thereof | |
DE602007010038D1 (de) | Pyrimidylderivate als proteinkinaseinhibitoren | |
TNSN06410A1 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists |